HALO — Halozyme Therapeutics, Inc.

Halozyme (HALO) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: Grew 38% year-over-year to $1.4 billion.
• Royalty Revenue: Increased 52% to $868 million, driven by strong performance of ENHANZE-enabled products.
• Net Income: $316.9 million, down from $444.1 million in 2024, impacted by a $285 million IPR&D expense from the Surf Bio acquisition.
• Adjusted EBITDA: $657.6 million, up from $632.2 million in 2024.
• GAAP Diluted EPS: $2.56, compared to $3.43 in 2024; Non-GAAP Diluted EPS: $4.15, down from $4.23.
• Fourth Quarter Revenue: Increased 52% to $451.8 million, with royalty revenue of $258 million, a 51% year-over-year increase.

2. Strategic Updates and Business Highlights

• Expanded portfolio from 2 to 4 subcutaneous drug delivery technologies through acquisitions of Elektrofi and Surf Bio.
• Achieved multiple regulatory approvals for ENHANZE-enabled products, including DARZALEX FASPRO and RYBREVANT, leading to 10 global blockbuster opportunities.
• Strong growth in key products:
  • DARZALEX: $14.4 billion in sales, generating $483 million in royalties.
  • PHESGO: Grew 48% to approximately $3 billion, yielding $105.6 million in royalties.
  • VYVGART Hytrulo: Revenue increased 90% to $4.15 billion, contributing $157.2 million in royalties.
• New collaborations in obesity and inflammatory bowel disease were established, diversifying the product pipeline.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenue of $1.71 billion to $1.81 billion, representing 22% to 30% growth.
• Royalty Revenue Guidance: Projected between $1.13 billion and $1.17 billion, a 30% to 35% increase.
• Adjusted EBITDA Guidance: Anticipated between $1.125 billion and $1.205 billion.
• Non-GAAP Diluted EPS: Expected to be between $7.75 and $8.25.
• Plans to support 6 new ENHANZE programs and 2 Hypercon programs entering Phase I clinical studies in 2026.

4. Bad News, Challenges, or Points of Concern

• Net Income Decline: Significant drop in net income due to IPR&D expenses related to acquisitions, raising concerns about profitability.
• Regulatory Risks: Potential challenges in transitioning existing products to subcutaneous formulations and navigating the regulatory landscape for new products.
• Market Competition: Increasing competition in the biopharma sector may impact future growth and market share, particularly as other companies explore similar delivery technologies.

5. Notable Q&A Insights

• DARZALEX Collaboration: Halozyme expects to extend its agreement with Johnson & Johnson beyond 2032, emphasizing the importance of continued collaboration.
• ADC Strategy: Regulatory pathways for converting ADCs to subcutaneous delivery will likely follow traditional PK non-inferiority studies, with potential for improved patient experiences.
• Hypercon Development: Two Phase I clinical trials for Hypercon products are anticipated to start in late 2026, with ongoing interest from partners in the technology.
• Auto-Injector Revenue Recognition: Revenue from auto-injectors will be recognized similarly to API sales, with royalties from commercial sales expected to follow.

This summary encapsulates the key points from Halozyme's Q4 2025 earnings call, highlighting financial performance, strategic initiatives, future outlook, and challenges faced by the company.